Vaccines: the road ahead

In order to play this media, we need your consent to add cookies to your device. Do you accept these cookies? Find out more.

Yes, accept cookies

The UK approved the first COVID-19 vaccine in early December, and the pandemic entered a new phase. While this is certainly a moment for optimism, vaccines bring new challenges around efficacy, distribution and public resistance. This week’s panel includes Caroline Naumann, Associate Director for Crisis and Security Consulting and also our COVID-19 Advisory Lead in EMEA,  and Joseph Smith, Senior Analyst responsible for providing analysis on international business issues as well as one of our leaders on analysis of the vaccine rollout.